Ghaffari et al., 2020 - Google Patents
COVID-19 serological tests: how well do they actually perform?Ghaffari et al., 2020
View HTML- Document ID
- 8619181496635992851
- Author
- Ghaffari A
- Meurant R
- Ardakani A
- Publication year
- Publication venue
- Diagnostics
External Links
Snippet
In only a few months after initial discovery in Wuhan, China, SARS-CoV-2 and the associated coronavirus disease 2019 (COVID-19) have become a global pandemic causing significant mortality and morbidity and implementation of strict isolation measures. In the …
- 200000000015 coronavirus disease 2019 0 title abstract description 71
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/543—Immunoassay; Biospecific binding assay with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ghaffari et al. | COVID-19 serological tests: how well do they actually perform? | |
| Kontou et al. | Antibody tests in detecting SARS-CoV-2 infection: a meta-analysis | |
| Khandker et al. | Diagnostic accuracy of rapid antigen test kits for detecting SARS-CoV-2: a systematic review and meta-analysis of 17,171 suspected COVID-19 patients | |
| Cui et al. | An updated review on SARS-CoV-2 infection in animals | |
| Strömer et al. | Kinetics of nucleo-and spike protein-specific immunoglobulin G and of virus-neutralizing antibodies after SARS-CoV-2 infection | |
| Al-Jighefee et al. | Evaluation of antibody response in symptomatic and asymptomatic COVID-19 patients and diagnostic assessment of new IgM/IgG ELISA kits | |
| James et al. | Comparison of serological assays for the detection of SARS-CoV-2 antibodies | |
| Savvateeva et al. | Microarray-based detection of antibodies against SARS-CoV-2 proteins, common respiratory viruses and type I interferons | |
| Heidepriem et al. | Longitudinal development of antibody responses in COVID-19 patients of different severity with ELISA, peptide, and glycan arrays: an immunological case series | |
| Tutukina et al. | IgG antibodies develop to spike but not to the nucleocapsid viral protein in many asymptomatic and light COVID-19 cases | |
| Chen et al. | Diagnostic accuracy of SARS-CoV-2 antigen tests for community transmission screening: a systematic review and meta-analysis | |
| Faizo et al. | A reliable indirect ELISA protocol for detection of human antibodies directed to SARS-CoV-2 NP protein | |
| Kučinskaitė-Kodzė et al. | Persistence of SARS-CoV-2-specific antibodies for 13 months after infection | |
| Alandijany et al. | Lack of antibodies to SARS-CoV-2 among blood donors during COVID-19 lockdown: a study from Saudi Arabia | |
| Alhazmi et al. | Community-based seroprevalence of SARS-CoV-2 antibodies following the first wave of the COVID-19 pandemic in Jazan Province, Saudi Arabia | |
| Souiri et al. | SARS-CoV-2-neutralizing antibody response and correlation of two serological assays with microneutralization | |
| Abravanel et al. | Diagnostic performance of an automated system for assaying anti-hepatitis E virus immunoglobulins M and G compared with a conventional microplate assay | |
| Sriburin et al. | Incidence of zika virus infection from a dengue epidemiological study of children in ratchaburi province, thailand | |
| Widyasari et al. | Performance evaluation of STANDARD Q COVID/FLU Ag Combo for detection of SARS-CoV-2 and influenza A/B | |
| Lu et al. | Comparison of two commercial ELISA kits for the detection of anti-dengue IgM for routine dengue diagnosis in Laos | |
| Xu et al. | A cross-sectional study of SARS-CoV-2 seroprevalence between fall 2020 and February 2021 in Allegheny County, Western Pennsylvania, USA | |
| Alidjinou et al. | Prospective evaluation of a commercial dengue NS1 antigen rapid diagnostic test in New Caledonia | |
| Hu et al. | Exploring rapid and effective screening methods for anti-SARS-CoV-2 neutralizing antibodies in COVID-19 convalescent patients and longitudinal vaccinated populations | |
| Socan et al. | Seroprevalence of anti-SARS-CoV-2 antibodies following the omicron BA. 1 wave | |
| Steininger et al. | Results of Tick-Borne Encephalitis Virus (TBEV) Diagnostics in an Endemic Area in Southern Germany, 2007 to 2022 |